Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Paul Declerck

Showing results (1-10 of 54) with videos related to

Pageof 6
Sort By:
Current Opinion in Pharmacology|December 28, 2020
Editorial: Gastrointestinal 2020: Novel inflammatory bowel disease treatments and therapeutic drug monitoringJoana Torres, Paul Declerck
Rheumatology (Oxford, England)|September 15, 2017
The road from development to approval: evaluating the body of evidence to confirm biosimilarityPaul Declerck, Mourad Farouk Rezk
Current Medical Research and Opinion|September 24, 2015
Biosimilars - terms of usePaul Declerck, Håkan Mellstedt, Silvio Danese
Pharmaceutical Research|September 19, 2015
Biosimilarity Versus Manufacturing Change: Two Distinct ConceptsPaul Declerck, Mourad Farouk-Rezk, Pauline M Rudd
Drugs|March 5, 2017
The Language of Biosimilars: Clarification, Definitions, and Regulatory AspectsPaul Declerck, Romano Danesi, Danielle Petersel, et al.
Oncotarget|March 24, 2018
Prolonged <i>in vivo</i> expression and anti-tumor response of DNA-based anti-HER2 antibodiesKevin Hollevoet, Elien De Smidt, Nick Geukens, et al.
International Journal of Environmental Research and Public Health|October 31, 2014
Effectiveness of the electronic cigarette: An eight-week Flemish study with six-month follow-up on smoking reduction, craving and experienced benefits and complaintsKarolien Adriaens, Dinska Van Gucht, Paul Declerck, et al.
Future Oncology (London, England)|August 24, 2019
The rise of oncology biosimilars: from process to promiseMark Verrill, Paul Declerck, Sibylle Loibl, et al.
Rheumatology and Therapy|January 18, 2020
Nonmedical Switching From Originators to Biosimilars: Does the Nocebo Effect Explain Treatment Failures and Adverse Events in Rheumatology and Gastroenterology?Roy Fleischmann, Vipul Jairath, Eduardo Mysler, et al.
Clinical Therapeutics|April 28, 2018
Monoclonal Antibody Biosimilars in Oncology: Critical Appraisal of Available Data on SwitchingPaul Declerck, Georgios Bakalos, Elias Zintzaras, et al.
Pageof 6

Showing results (1-10 of 54) with videos related to

Sort By:
Pageof 6
Current Opinion in Pharmacology|December 28, 2020
Editorial: Gastrointestinal 2020: Novel inflammatory bowel disease treatments and therapeutic drug monitoringJoana Torres, Paul Declerck
Rheumatology (Oxford, England)|September 15, 2017
The road from development to approval: evaluating the body of evidence to confirm biosimilarityPaul Declerck, Mourad Farouk Rezk
Current Medical Research and Opinion|September 24, 2015
Biosimilars - terms of usePaul Declerck, Håkan Mellstedt, Silvio Danese
Pharmaceutical Research|September 19, 2015
Biosimilarity Versus Manufacturing Change: Two Distinct ConceptsPaul Declerck, Mourad Farouk-Rezk, Pauline M Rudd
Drugs|March 5, 2017
The Language of Biosimilars: Clarification, Definitions, and Regulatory AspectsPaul Declerck, Romano Danesi, Danielle Petersel, et al.
Oncotarget|March 24, 2018
Prolonged <i>in vivo</i> expression and anti-tumor response of DNA-based anti-HER2 antibodiesKevin Hollevoet, Elien De Smidt, Nick Geukens, et al.
International Journal of Environmental Research and Public Health|October 31, 2014
Effectiveness of the electronic cigarette: An eight-week Flemish study with six-month follow-up on smoking reduction, craving and experienced benefits and complaintsKarolien Adriaens, Dinska Van Gucht, Paul Declerck, et al.
Future Oncology (London, England)|August 24, 2019
The rise of oncology biosimilars: from process to promiseMark Verrill, Paul Declerck, Sibylle Loibl, et al.
Rheumatology and Therapy|January 18, 2020
Nonmedical Switching From Originators to Biosimilars: Does the Nocebo Effect Explain Treatment Failures and Adverse Events in Rheumatology and Gastroenterology?Roy Fleischmann, Vipul Jairath, Eduardo Mysler, et al.
Clinical Therapeutics|April 28, 2018
Monoclonal Antibody Biosimilars in Oncology: Critical Appraisal of Available Data on SwitchingPaul Declerck, Georgios Bakalos, Elias Zintzaras, et al.
Pageof 6